ClinicalTrials.gg
CompletedNCT02986321PIONEERUpdated Jan 28, 2019

A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD

A Phase 2 interventional study of CHF6001 and Budesonide in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-01-28.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,130
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tanimilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
3rd of 12
1,130 · median 46
Started
2016
with 2 others
Phase 2
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
12 of 12
Chiesi Farmaceutici S.p.A.

Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 3 that started in 2016, is one of 3 in phase 2, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tanimilast

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The purpose of this study is to evaluate the dose-response relationship of different doses of CHF6001 and to identify the optimal dose (s) in terms of benefit/risk ratio for further development in the target patient population.

Read the detailed description

This is a phase II, randomized, double-blind, double-dummy, placebo and active controlled multinational, multicenter, dose ranging, 6-arm parallel-group study to identify the optimal dose of CHF6001, PDE4 inhibitor under development, with respect to lung functions and symptoms.

After a 2-wk run-in period under formoterol (Oxis Turbohaler®) and rescue salbutamol prn, patients will be randomized to one of the 6 treatment groups. After the randomization, patients will be assessed after 3, 6, 12, 18 and 24 weeks of treatment at clinic/hospital. A follow-up visit will be performed 12 days after the last visit.

During the study, patients will report daily symptoms with the EXACT-PRO/E-RS questionnaire, rescue/background medication use and compliance with the study medications. AEs, SAEs and COPD exacerbations will be monitored throughout the study. At randomization and subsequent visits, patients will undergo physical and vital signs examinations, spirometry measurement, 12-lead ECG. Symptoms and Health status will be assessed through validated questionnaires. Routine lab analysis and blood biomarkers will be done.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • anti-inflammatory respiratory drug
  • PDE4 inhibitor
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients
  • Non- or woman permanently sterilized or on one or more highly effective
  • Current/ex smokers (history > 10 pack years)
  • Post bronchodilatator >=30% and \<=70% predicted normal value and FEV1/FVC ratio \<0.7
  • Documented history of at least 1 moderate or severe exacerbation in the 12 months prior to study entry
  • Symptomatic patients (MMRC score ≥2 and a CAT score ≥10)
  • Patients on daily maintenance therapy with an ICS/LABA .

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of asthma or other respiratory disorders
  • Maintenance bronchodilators therapy only (eg LABA alone)
  • Maintenance triple therapy.
  • Occurrence of a moderate or severe exacerbation within 6 weeks prior to study entry or during the run-in period.
  • Patients requiring long term oxygen therapy.
  • Concomitant or recent pulmonary rehabilitation programme
  • Known respiratory disorders other than COPD
  • Lung cancer or a history of lung cancer, active or history of cancer with less than 5 years disease free survival time
  • to β2-agonist, , PDE4 inhibitors or any of the
  • Depression, generalised anxiety disorder, suicidal ideation
  • Any cardiovascular disease (IM, CHF III/IV; AF not controlled by therapy, etc) within 1 year of study entry
  • Any relevant clinically significant cardiovascular condition, clinically abnormal significant 12-lead (>450 ms for male and >470 for female) or clinically significant laboratory abnormalities
  • Serum potassium value ≤3.5 mEq/L or >5.5mEq/L and/or a fasting serum glucose value ≥140 mg/dL.
  • History or symptoms of significant neurological disease
  • Unstable concurrent disease: eg uncontrolled Thyroid disease or other endocrine diseases, gastrointestinal uncontrolled disease, uncontrolled immune diseases
  • Renal impairment.
  • Patients with abnormal and/ or aspartate aminotransferase and/or
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities and patients receiving treatment with any drug known to have a well defined potential for hepatotoxicity before Study entry
  • Severely obese ( ≥35 kg/m2) or have experienced excessive weight loss recently
  • History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening visit.
  • Any recent participation to a clinical Study with other drug
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,130 participants (actual)

Study arms

  • Experimental
    CHF6001 DOSE1

    DOSE1

    Drug: CHF6001

  • Experimental
    CHF6001 DOSE2

    DOSE2

    Drug: CHF6001

  • Experimental
    CHF6001 DOSE3

    DOSE3

    Drug: CHF6001

  • Experimental
    CHF6001 DOSE4

    DOSE4

    Drug: CHF6001

  • Placebo comparator
    Matched placebo

    placebo control

    Drug: Placebo

  • Active comparator
    Budesonide

    Budesonide DPI 800µg

    Drug: Budesonide

Interventions

  • Dose response: Test one of 4 different doses of CHF6001

    Also known as: Dose range finding

  • active control

    Also known as: Active comparator

  • DrugPlacebo

    placebo control

06

What researchers measure

Primary outcomes

  1. Change from baseline in predose morning FEV1 at 12 weeks

    overall effect of CHF6001 on change from baseline in predose morning FEV1

    Time frame: week 12

Secondary outcomes

  1. Change from baseline in predose morning FEV1 at other timepoints

    Change from Baseline

    Time frame: weeks 3, 6, 18, 24

  2. Change from baseline in pre-dose morning IC

    Change from Baseline for other lung function parameters

    Time frame: weeks 3, 6, 12, 18, 24

  3. Change from baseline in pre-dose morning FVC

    Change from Baseline for other lung function parameters

    Time frame: weeks 3, 6, 12, 18, 24

  4. Change from baseline in TDI focal score

    Change of TDI score

    Time frame: weeks 3, 6, 12, 18, 24

  5. Change from baseline in SGRQ score

    Change of SGRQ score

    Time frame: weeks 3, 6, 12, 18, 24

  6. Change from baseline in E-RS score

    Change of E-RSI score

    Time frame: weeks 3, 6, 12, 18, 24

  7. COPD exacerbation rate over 24 weeks of treatment

    exacerbation rate

    Time frame: 24 weeks

  8. Time to first COPD exacerbation

    Time to first COPD exacerbation

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Singh D, Emirova A, Francisco C, Santoro D, Govoni M, Nandeuil MA. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. Respir Res. 2020 Sep 22;21(1):246. doi: 10.1186/s12931-020-01512-y. PubMed 32962709 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Oct 2017, 9 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2016
First posted
Dec 8, 2016
StartActual
Dec 15, 2016
Primary completionActual
Oct 4, 2017
CompletionActual
Jan 9, 2018
Last update
Jan 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02986321
Responsible party
Sponsor
First posted
Dec 8, 2016
Start date
Dec 15, 2016
Primary completion
Oct 4, 2017
Completion
Jan 9, 2018
Last update
Jan 28, 2019

Study contacts

Dave Singh
principal investigator · Medicines Evaluation Unit, Manchester, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion